Dr. Emilia Javorsky

But I think it's important to look at the graveyard of things that have already failed due to misaligned incentives in our current system.

So I think the really great place to look at this is in antibiotics.

So there's been many companies that have

discovered new antibiotics, including ones that have been AI discovered that look really promising and the data looks really good.

And you start to take them into clinical trials and the clinical trials look really good.

And you're like, this is so exciting.

Like this is working.

We have a new therapy.

There's a huge unmet need.

Problem is, it doesn't meet the financial requirements to actually make it over the finish line and go through the FDA.

And so antibiotics are something you only take once, right?

You're not taking them every day.

You take them when you get an infection.

And by nature of the antibiotic resistance problem, like you don't want to use them too much, right?

You want to use them sparingly.

You want to use the new stuff only when you have to, only when the other stuff has failed.

And so what that means is there isn't really a viable business model, right?

This is not going to be a billion dollar a year project.

Then why do I bother sort of take it through the FDA?

Yeah, there's two things I want to say here.